DSpace Repository

Classical and novel roles of p53 and prospects for anticancer therapy

Show simple item record

dc.creator Fuster, José J.
dc.creator Sanz-González, Silvia M.
dc.creator Moll, Ute M.
dc.creator Andrés, Vicente
dc.date 2008-05-14T08:14:22Z
dc.date 2008-05-14T08:14:22Z
dc.date 2007-05
dc.date.accessioned 2017-01-31T01:17:23Z
dc.date.available 2017-01-31T01:17:23Z
dc.identifier Trends Mol Med 13 (5): 192-199
dc.identifier http://hdl.handle.net/10261/4227
dc.identifier 10.1016/j.molmed.2007.03.002
dc.identifier.uri http://dspace.mediu.edu.my:8181/xmlui/handle/10261/4227
dc.description The definitive version is available at http://www.sciencedirect.com/science/journal/14714914
dc.description The tumor suppressor p53 is a transcription factor that is frequently inactivated in human tumors. Therefore,restoring its function has been considered an attractive approach to restrain cancer. Typically, p53-dependent growth arrest, senescence and apoptosis of tumor cells have been attributed to transcriptional activity of nuclear p53. Notably, wild-type p53 gain-of-function enhances cancer resistance in the mouse, but it also accelerates aging in some models, possibly due to altered p53 activity. Therefore, the emerging evidence of mitochondrial transcription-independent activities of p53 has raised high expectations. Here, we review new developments in transcription-dependent and transcription-independent p53 functions, recent advances in targeting p53 for cancer treatment and the pitfalls of moving from the laboratory research to the clinical setting.
dc.description This Work in the laboratory of V.A. is supported by grants from Ministerio de Sanidad y Consumo/Instituto de Salud Carlos III (Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares RECAVA), from Sociedad Española de Cardiología, and from Ministerio de Educación y Ciencia and the European Regional Development Fund (SAF2004–03057). Work in the laboratory of U.M.M. is supported by the Nacional Cancer Institute and Philip Morris USA Inc. and Philip Morris International. J.J.F. is supported by a CSIC-I3P program pre-doctoral fellowship cosponsored by the European Social Fund
dc.description Peer reviewed
dc.format 1674528 bytes
dc.format application/pdf
dc.language eng
dc.publisher Elsevier
dc.relation http://dx.doi.org/10.1016/j.molmed.2007.03.002
dc.rights openAccess
dc.subject p53
dc.subject MDM2
dc.subject Cancer
dc.subject Aging
dc.subject Mitochondria
dc.subject Genetically-engineered mice
dc.subject Anticancer therapy
dc.title Classical and novel roles of p53 and prospects for anticancer therapy
dc.type Artículo

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account